ANG
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Ang Lifesciences India Ltd - Names Saruchi Gupta As CFO
ANG Lifesciences India Ltd AGLI.BO:
ANG LIFESCIENCES INDIA LTD - NAMES SARUCHI GUPTA AS CFO
Source text for Eikon: ID:nBSE96LGRz
Further company coverage: AGLI.BO
ANG Lifesciences India Ltd AGLI.BO:
ANG LIFESCIENCES INDIA LTD - NAMES SARUCHI GUPTA AS CFO
Source text for Eikon: ID:nBSE96LGRz
Further company coverage: AGLI.BO
Events:
Bonus
Dividend
Bonus
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does ANG Lifesciences do?
ANG Lifesciences India is an ISO-9001:2008 certified company that manufactures sterile dry powder vials for various medical purposes in compliance with GMP requirements, utilizing modern equipment and techniques as per WHO G.M.P. and G.L.P. norms.
Who are the competitors of ANG Lifesciences?
ANG Lifesciences major competitors are Vilin Bio Med, Guj. Terce Lab, Chandra Bhagat Pharm, Panjon, Guj. Inject (Kerala), Unick Fix-A-Form, Concord Drugs. Market Cap of ANG Lifesciences is ₹39 Crs. While the median market cap of its peers are ₹36 Crs.
Is ANG Lifesciences financially stable compared to its competitors?
ANG Lifesciences seems to be less financially stable compared to its competitors. Altman Z score of ANG Lifesciences is 1.3 and is ranked 7 out of its 8 competitors.
Does ANG Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. ANG Lifesciences latest dividend payout ratio is 2.57% and 3yr average dividend payout ratio is 2.57%
How has ANG Lifesciences allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is ANG Lifesciences balance sheet?
ANG Lifesciences balance sheet is weak and might have solvency issues
Is the profitablity of ANG Lifesciences improving?
No, profit is decreasing. The profit of ANG Lifesciences is -₹12.41 Crs for TTM, -₹10.14 Crs for Mar 2024 and -₹0.26 Crs for Mar 2023.
Is the debt of ANG Lifesciences increasing or decreasing?
Yes, The net debt of ANG Lifesciences is increasing. Latest net debt of ANG Lifesciences is ₹76.8 Crs as of Mar-25. This is greater than Mar-24 when it was ₹58.09 Crs.
Is ANG Lifesciences stock expensive?
ANG Lifesciences is not expensive. Latest PE of ANG Lifesciences is 0.0, while 3 year average PE is 14.04. Also latest EV/EBITDA of ANG Lifesciences is 0.0 while 3yr average is 33.79.
Has the share price of ANG Lifesciences grown faster than its competition?
ANG Lifesciences has given lower returns compared to its competitors. ANG Lifesciences has grown at ~-43.34% over the last 1yrs while peers have grown at a median rate of 11.28%
Is the promoter bullish about ANG Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in ANG Lifesciences is 70.6% and last quarter promoter holding is 70.6%.
Are mutual funds buying/selling ANG Lifesciences?
There is Insufficient data to gauge this.